SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A highlight strong growth prospects, including raised revenue guidance, increased customer base, and strategic investments in high ROI activities. Despite uncertainties in the pharma segment, the company shows balanced growth across sectors and a positive trend in net dollar retention. Cost optimizations and improved cash burn, along with optimistic guidance, contribute to a positive outlook. The market expansion and customer growth further support a positive sentiment, likely leading to a stock price increase in the short term.
Key Financial Performance
Revenue Growth 22% revenue growth in the fourth quarter of 2025 compared to the same period in 2024. Excluding biopharma, clinical revenue grew 31% year-over-year. Reasons for growth include strong performance in EMEA, North America, Asia Pacific, and Latin America, as well as increased adoption of SOPHiA DDM by new customers.
Regional Revenue Growth EMEA grew 22% in Q4 2025, with clinical revenue up 35% year-over-year. Belgium and Germany contributed significantly, growing 93% and 66%, respectively. North America analysis volumes grew 45% year-over-year, while Asia Pacific saw 44% revenue growth, driven by India and Australia. Latin America experienced 49% revenue growth, with Mexico and Brazil growing 95% and 48%, respectively. Reasons include major customer wins and increased adoption of genomic testing.
Platform Analysis Volume Over 105,000 analyses in Q4 2025, up 16% from 91,000 in Q4 2024. For the full year, platform analysis volume was over 391,000, up from 352,000 in 2024. Growth attributed to increased customer adoption and larger data volumes processed.
Gross Profit and Margin Gross profit for Q4 2025 was $14.7 million, up 21% from $12.1 million in Q4 2024. Gross margin was 67.7%, slightly down from 68.2% in Q4 2024. Adjusted gross profit for Q4 was $16 million, up 22% year-over-year, with adjusted gross margin at 73.9%, down 30 basis points. Full-year gross profit was $52.1 million, up 19%, with gross margin flat at 67.4%. Adjusted gross margin for the year increased by 140 basis points to 74.2%, driven by compute optimizations and reduced scrap costs.
Operating Expenses Total operating expenses for Q4 2025 were $33.2 million, up from $29.5 million in Q4 2024. Full-year operating expenses were $123 million, up from $110.5 million in 2024. Reasons include foreign exchange impacts, legal expenses related to patent litigation, and targeted investments in sales and marketing.
Net Dollar Retention Net dollar retention increased to 115% in 2025, up from 104% in 2024. This reflects strong same-store growth and the adoption of additional applications by existing customers.
Customer Growth 124 new customers signed in 2025, with 30 added in Q4. Average contract value of new customers increased by 120% year-over-year. Total core genomic customers reached 528 by year-end, up from 472 in 2024. Reasons include strong demand for SOPHiA DDM and successful implementation efforts.
Cash Burn Total cash burn for 2025 was $50.4 million, improving 6% from $53.7 million in 2024. Q4 cash burn was $12.3 million, down from $12.8 million in Q4 2024. Improvements attributed to cost optimizations and increased revenue.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SOPHiA DDM Digital Twins: Launched to create AI-driven virtual representations of individual patients, enabling simulation of treatment scenarios for personalized care. Initial focus on lung cancer.
Enhanced SOPHiA DDM platform: Modernized platform with 10x greater capacity, enabling whole genome analysis in under 6 hours and doubling data processing capacity per week.
Global customer base expansion: Added 124 new customers in 2025, reaching a total of 993 customers across 75 countries.
Regional growth: Strong revenue growth in EMEA (22%), North America (45% analysis volume growth), Asia Pacific (44%), and Latin America (49%).
Major U.S. healthcare systems: Signed two of the largest U.S. healthcare systems, supporting genomic testing for up to 60,000 patients annually.
Data processing efficiency: Processed nearly 1 petabyte of genomic data in 2025, reflecting a shift to more comprehensive tests and advanced computational interpretations.
Customer satisfaction: Net Promoter Score of 67, customer satisfaction over 97%, and annualized revenue churn below 1%.
Leadership transition: Ross Muken to become CEO in July 2026, with Jurgi Camblong transitioning to Executive Chairman to focus on innovation.
Partnerships: Collaborated with MD Anderson for whole transcriptome test development and renewed agreement with AstraZeneca for AI-driven projects.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Foreign Exchange Volatility: The strengthening of the Swiss franc and euro against the U.S. dollar has increased operating expenses when reported in U.S. dollars, adversely impacting financial results.
Litigation Costs: Guardant Health filed patent infringement claims, resulting in $1.8 million in legal expenses. Although provisional measures were rejected, the litigation has added financial strain.
Seasonal Revenue Variability: Revenue growth is expected to be back-half weighted in 2026, with softer performance in Q1 due to seasonality and delayed revenue realization from new customer implementations.
Implementation Delays: New customer implementations, including two large U.S. health systems, are not expected to generate meaningful revenue until late 2026, delaying revenue realization.
Cloud Compute Costs: Despite optimizations, the increasing volume and complexity of genomic data processed could pressure cloud compute and storage costs.
Regulatory and Validation Challenges: The healthcare industry requires rigorous validation and clinical evidence, which can slow down the adoption of new AI-driven solutions.
Economic Uncertainty: Macroeconomic uncertainties, including currency fluctuations and potential economic downturns, could impact financial performance and operational costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: SOPHiA GENETICS expects full year reported revenue to be between $92 million and $94 million in 2026, representing 20% to 22% growth. Growth is expected to be back-half weighted as new business signed in 2025 comes online in the second half of the year.
Adjusted EBITDA: The company expects adjusted EBITDA loss to be between $29 million and $32 million in 2026, with plans to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027.
Gross Margins: Gross margins are expected to expand slightly in 2026 due to targeted investments in platform optimization, including cloud compute and storage cost reductions.
Growth Drivers: Key growth drivers for 2026 include continued execution and growth in the United States, expansion of the liquid biopsy application MSK-ACCESS, and renewed momentum in the biopharma offering.
Customer Implementation: The company implemented a record 102 new customers in 2025, with many expected to generate revenue in 2026. Two large U.S. health systems are expected to reach routine usage by Q4 2026.
Biopharma Partnerships: SOPHiA GENETICS renewed its global commercial agreement with AstraZeneca and signed a new global commercial agreement with a top 5 global pharmaceutical company, signaling strong biopharma demand.
Product Development: The company plans to explore new applications in 2026, including MRD, solid tumor, and DNA methylation, as well as the co-development of a whole transcriptome test in partnership with MD Anderson.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Your guidance is for 21% growth at the midpoint. Can you walk us through what contributions you're expecting from key growth drivers such as MSK-ACCESS, IMPACT, and from rare disease?
A:The company ended the year strong with 31% revenue growth year-on-year in Q4 and strong ACV signings. MSK-ACCESS is a key driver, with sizable customers coming online and ramping up. IMPACT has seen material wins in both ex-U.S. and native markets, gaining share in the solid tumor vertical. Rare inherited diseases are also seeing great uptake, particularly with the enhanced exome product. Overall, growth is balanced across oncology, diagnostics, and NGS.
Q:The net dollar retention was up meaningfully to 115%. Can you speak to what drove the gross selling strength here and if you expect this to continue in 2026?
A:The reacceleration in NDR is attributed to churn being under 1%, showcasing the platform's stickiness. There is a reacceleration of volumes in NGS, oncology, and rare disease. The company has also improved in enabling customers to scale with data compute, higher ASPs, and bigger volumes. This trend is expected to continue into 2026 and beyond, supported by over 200 new accounts added in the last two years.
Q:On the pharma side, can you give us any sense of the potential annual contribution from new contracts and the time period over which we would see that revenue begin to roll in?
A:The pharma business has shown improved momentum with new contracts and logos. While the contribution to 2026 will be positive, the business is long-cycle and not yet at critical mass to declare specific revenue percentages. The company is laying groundwork for reacceleration in 2026, 2027, and beyond, with aspirations for pharma to become a higher percentage of total revenue.
Q:On the two large health systems added, what is the potential for these customers to expand into additional indications, and what are the key components influencing their decision?
A:The two large health systems are starting with one application, with significant growth potential. One of the systems already has an expansion opportunity in the pipeline. These accounts could grow materially over time, potentially reaching 8-figure revenue contributions. The ability to handle new platforms, applications, and scalability at a cost-effective rate is expected to drive further expansion.
Q:What does the 2026 guide contemplate for volumes and price/mix, and should we expect price/mix growth to accelerate?
A:The company expects ASPs to increase, driven by higher-priced tests like MSK-ACCESS and IMPACT Flex. While some lower ASP volumes from regions like Latin America and India may temper growth, overall volume growth is expected to remain strong, with ASP lift contributing to revenue growth.
Q:As the new CEO, what changes or approaches do you foresee in the next year or two?
A:The focus will be on scaling the business beyond the $100 million revenue mark, preparing the organization for substantial growth. The company aims to unlock the full value of its platform and network, particularly in areas like AI, multimodal algorithms, and digital biomarkers. Investments will be made in products like Digital Twins to build a differentiated intelligence layer for healthcare.
Q:Can you give a sense of your go-live implementation timelines and infrastructure for turning customers live in 2026?
A:The company completed over 100 implementations in 2025, with momentum improving in the second half of the year. Efforts to optimize the implementation process have resulted in quicker time to revenue. Standardized products like MSK-IMPACT and enhanced exome are enabling faster implementations.
Q:Do you think you can build off the 50% U.S. analysis volume growth in Q4, and how do you view the size of your U.S. sales operation?
A:The U.S. market is expected to grow significantly, with potential for even higher growth in 2026 as large customers come online. The company plans to add headcount to its U.S. sales team but will do so incrementally, as its model allows for high revenue per salesperson. The focus is on signing entire health systems rather than individual clinicians.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue contributions or percentages for the pharma business, citing its long-cycle nature and lack of critical mass. They also did not provide exact figures for the potential revenue from the two large health systems, instead offering general optimism about their growth potential.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADAM Innovations
AI algorithm
AI health
ATM facility
AZ
Digital Twins
Executive Chairman
FX impact
Florida
Full Conference
Guardant
Mexico
National
Onc
School Medicine
accomplishment
amount
analysis hour
approach
biopharma
borrowing stock
care decade
cash borrowing
employee
franc
generation
health care
litigation
lung cancer
overview
patient AI
proceeds
record booking
result Platform
sale FX
scalability
stickiness
stream
test
world AI
SOPH Transcript
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary indicates positive aspects such as revenue growth, strong net dollar retention, and strategic partnerships. The Q&A section adds confidence in customer onboarding and ASP trends, despite some regional challenges. The company's strategic focus on biopharma and platform expansion, along with optimistic guidance, suggests a favorable market reaction. While cash burn increased, it was due to strategic investments. Overall, the sentiment is positive, with strong growth drivers and strategic partnerships likely supporting a stock price increase.
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call summary and Q&A highlight strong growth prospects, including raised revenue guidance, increased customer base, and strategic investments in high ROI activities. Despite uncertainties in the pharma segment, the company shows balanced growth across sectors and a positive trend in net dollar retention. Cost optimizations and improved cash burn, along with optimistic guidance, contribute to a positive outlook. The market expansion and customer growth further support a positive sentiment, likely leading to a stock price increase in the short term.
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call presents a positive outlook with strong financial metrics, including a 13% YoY improvement in adjusted EBITDA and stable customer retention. The AstraZeneca partnership and growth in clinical and biopharma segments are promising, despite conservative guidance. The Q&A reveals strong momentum and optimism for 2026, with significant potential from MSK-ACCESS and biopharma segments. While some details remain confidential, overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong U.S. market growth, improved gross margins, and significant partnership expansion with AstraZeneca, which is the largest in the company's history. Despite an increase in operating loss, the company's strategic focus on new applications, customer growth, and cost management reflect a positive outlook. The Q&A section reinforces this sentiment with optimistic guidance on product adoption and contract value increases. Although management was conservative about disclosing specific contract sizes, the overall narrative suggests positive momentum, warranting a 'Positive' sentiment rating.
SOPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
